Selective Immunosuppressive Polypeptides for Targeted Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunosuppressive therapies for inflammatory, autoimmune, allergic, and infectious diseases, as well as organ rejection, suffer from nonspecific action, leading to increased vulnerability to infections and neoplasms, along with adverse effects such as nephrotoxicity, hepatotoxicity, and chronic conditions.
Innovation Solution
Development of polypeptides with selective immunosuppressive activity, encoded by specific polynucleotides, which inhibit antibody production with minimal adverse effects, using sequences such as those presented in SEQ ID NOs: 2, 3, 5, and 9, and their use in pharmaceutical compositions for targeted immunosuppression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current immunosuppressants are used to treat inflammatory, autoimmune, allergic, and infectious diseases, then immunosuppression is achieved, but vulnerability to infections and neoplasms increases due to nonspecific action
Solution Approach 1:
The patent segments the immune system into specific targets (B cells, T cells, macrophages, dendritic cells) and develops polypeptides that selectively modulate each cell type's function. This targeted approach replaces the nonspecific suppression of current immunosuppressants with precise, cell-type-specific regulation, achieving immunosuppression while preserving protective immune functions against infections and neoplasms
Solution Approach 2:
The patent applies local quality by designing polypeptides with specific functions tailored to different immune cell types. Each polypeptide is engineered to interact with particular cell surface receptors or intracellular pathways of specific immune cells, creating localized, selective immunomodulation rather than global suppression. This ensures that only pathological immune responses are suppressed while maintaining protective immunity
2Reliability
If current immunosuppressants are used to prevent organ rejection, then rejection is prevented, but adverse effects such as nephrotoxicity, hepatotoxicity, and chronic conditions occur
Solution Approach 1:
The patent uses polypeptides as intermediary agents that mediate selective immunosuppression through specific cellular mechanisms. These polypeptides act as intermediaries between the therapeutic goal (preventing organ rejection) and the immune system, providing controlled suppression of transplant rejection while avoiding the direct toxic effects of conventional immunosuppressants on kidneys, liver, and other organs
Solution Approach 2:
The patent employs recombinant DNA technology to produce identical copies of therapeutic polypeptides through genetic engineering. This allows for consistent, pure, and scalable production of the immunomodulatory polypeptides, ensuring therapeutic efficacy while eliminating the toxic side effects associated with conventional immunosuppressive drugs
3Reliability
If conventional immunosuppressants are used, then immune response is reduced, but nonspecific action leads to loss of ability to distinguish between self and non-self
Solution Approach 1:
The patent introduces dynamic, condition-dependent immunomodulation where polypeptides are designed to activate or inhibit specific immune pathways only under pathological conditions. The polypeptides dynamically respond to disease states by selectively suppressing aberrant immune responses while preserving normal self-tolerance mechanisms, thereby maintaining the immune system's ability to distinguish between self and non-self
Data Source
Figure 1
Figure 2
Figure 3
AI summary
This invention refers to polynucleotides and non-hemorrhagic and non-immunogenic polypeptides of selective immunosuppressive activity on production of antibodies to antigens of different natures. The polypeptides described herein are useful for preparing pharmaceutical compositions for prevention or treatment of conditions that require immunosuppression, preferably, inflammatory, autoimmune, allergic and infectious diseases and rejection to transplanted organs.